(Q40873139)

24 September 2017

title

Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas (English)

1 reference

24 September 2017

1 reference

R Palumbo

1

1 reference

24 September 2017

S Palmeri

2

1 reference

24 September 2017

M Antimi

3

1 reference

24 September 2017

C Gatti

4

1 reference

24 September 2017

P Raffo

5

1 reference

24 September 2017

G Villani

6

1 reference

24 September 2017

S Toma

7

1 reference

24 September 2017

publication date

1 November 1997

1 reference

24 September 2017

1 reference

24 September 2017

volume

8

1 reference

24 September 2017

issue

11

1 reference

24 September 2017

page(s)

1159-1162

1 reference

Doxorubicin (or epidoxorubicin) combined with ifosfamide in the treatment of adult advanced soft tissue sarcomas

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008279426654

7 January 2021

Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008279426654

7 January 2021

Bone marrow autotransplantation for solid tumors--prospects

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008279426654

7 January 2021

Ifosfamide plus mesna with and without adriamycin in soft tissue sarcoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008279426654

7 January 2021

Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008279426654

7 January 2021

Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008279426654

7 January 2021

High-dose ifosfamide with mesna uroprotection: a phase I study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008279426654

7 January 2021

High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008279426654

7 January 2021

High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008279426654

7 January 2021

Ambulatory 4-day continuous-infusion schedule of high-dose ifosfamide with mesna uroprotection and granulocyte colony-stimulating factor in advanced solid tumours: a phase I study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008279426654

7 January 2021

Feasibility and compliance of epirubicin plus ambulatory continuous infusion ifosfamide at escalating doses in advanced soft tissue sarcomas: a phase I study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008279426654

7 January 2021

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008279426654

7 January 2021

Results of salvage surgery for metastatic sarcomas

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008279426654

7 January 2021

Five-year survival after pulmonary metastasectomy for adult soft tissue sarcoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008279426654

7 January 2021

Survival after pulmonary metastasectomy in soft tissue sarcoma. Prognostic factors in 214 patients.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008279426654

7 January 2021

Identifiers

DOI

10.1023/A:1008279426654

1 reference

24 September 2017

1 reference